Rare Disease Therapies And Expanded Diagnoses Will Drive Strong Long Term Upside

Catalysts

About Pharming Group

Pharming Group is a rare disease biotechnology company focused on developing and commercializing innovative therapies for patients with significant unmet medical needs.

What are the underlying business or industry changes driving this perspective?

• Ongoing double-digit growth of RUCONEST in severe HAE patients, supported by its differentiated clinical profile and limited competitive impact in this high-need niche, is likely to sustain a durable cash engine and support continued revenue expansion and stable to improving gross margins.
• Rapid uptake of Joenja in the currently approved 12 years and older APDS population, coupled with strong adherence and a growing base of identified patients, underpins a multi-year volume ramp that can meaningfully increase total revenues and operating leverage.
• Imminent U.S. pediatric approval for Joenja, with dozens of already identified 4 to 11-year-old APDS patients and early access conversions expected, should create a near-term step-up in treated patient numbers and accelerate earnings growth.
• Broader diagnostic and genetic reclassification efforts in APDS and related immune dysregulation disorders, including large-scale VUS work and AI-enabled patient finding, could materially expand the addressable population over time and drive sustained top line growth.
• Focused international rollout of Joenja in selected high-value markets and continued optimization of the cost base, including exiting low-return RUCONEST geographies and reducing G and A head count, should enhance profit margins and free additional capital for pipeline and commercial investment.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Pharming Group's revenue will grow by 3.2% annually over the next 3 years.
• Analysts assume that profit margins will increase from 0.1% today to 8.7% in 3 years time.
• Analysts expect earnings to reach $34.4 million (and earnings per share of $0.05) by about December 2028, up from $382.0 thousand today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $135.3 million in earnings, and the most bearish expecting $-48.4 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 33.7x on those 2028 earnings, down from 3035.5x today. This future PE is lower than the current PE for the GB Biotechs industry at 3035.5x.
• Analysts expect the number of shares outstanding to decline by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.39%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The long-term competitive landscape in hereditary angioedema is shifting toward more convenient oral and emerging therapies. While management stresses RUCONEST's niche in severe and refractory patients, over time physicians may favor simpler options for a broader share of patients, which could erode RUCONEST volumes and slow revenue growth.
• Pharming is concentrating future growth on Joenja and a small number of late stage rare disease programs. Any delay, negative data readout or regulatory setback in APDS label expansions, PID and CVID basket trials or the KL1333 mitochondrial disease study would remove key growth pillars and compress earnings and net margins.
• The strategy to exit lower return RUCONEST geographies and rely more heavily on the U.S. market and selected high value international launches increases dependence on pricing and reimbursement outcomes in a few territories. Any pricing pressure or access hurdles could weigh on revenue and operating profit.
• Expansion of the APDS opportunity depends on complex genetic reclassification work, VUS resolution and AI driven patient finding. If real world prevalence proves materially lower than suggested by early research or if labs and payers are slow to adopt these methods, Joenja's long term patient pool may fall short of expectations, limiting top line growth.
• Management is pursuing disciplined capital allocation alongside potential future M&A and a rapidly scaling cost base. If acquisitions such as Abliva do not deliver expected returns or if R&D and commercial investments outpace revenue realization, the company could see margin compression and weaker earnings growth despite rising sales.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of €2.11 for Pharming Group based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €2.45, and the most bearish reporting a price target of just €1.7.
  
• In order for you to agree with the analysts, you'd need to believe that by 2028, revenues will be $397.8 million, earnings will come to $34.4 million, and it would be trading on a PE ratio of 33.7x, assuming you use a discount rate of 5.4%.
  
• Given the current share price of €1.46, the analyst price target of €2.11 is 31.1% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.